Publication Information

{'id': 'https://openalex.org/W2071686517', 'doi': 'https://doi.org/10.1158/1538-7445.am2011-1737', 'title': 'Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib', 'display_name': 'Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib', 'publication_year': 2011, 'publication_date': '2011-04-01', 'ids': {'openalex': 'https://openalex.org/W2071686517', 'doi': 'https://doi.org/10.1158/1538-7445.am2011-1737', 'mag': '2071686517'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2011-1737', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5066605048', 'display_name': 'Ruth Bennett', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I40120149', 'display_name': 'University of Oxford', 'ror': 'https://ror.org/052gg0110', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I40120149']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Ruth Bennett', 'raw_affiliation_strings': ['1Oxford University, Oxford, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': '1Oxford University, Oxford, United Kingdom.', 'institution_ids': ['https://openalex.org/I40120149']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5036009351', 'display_name': 'Merel Gijsen', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I40120149', 'display_name': 'University of Oxford', 'ror': 'https://ror.org/052gg0110', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I40120149']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Merel Gijsen', 'raw_affiliation_strings': ['1Oxford University, Oxford, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': '1Oxford University, Oxford, United Kingdom.', 'institution_ids': ['https://openalex.org/I40120149']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5071537151', 'display_name': 'Anthony Kong', 'orcid': 'https://orcid.org/0000-0002-3989-3948'}, 'institutions': [{'id': 'https://openalex.org/I40120149', 'display_name': 'University of Oxford', 'ror': 'https://ror.org/052gg0110', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I40120149']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Anthony Kong', 'raw_affiliation_strings': ['1Oxford University, Oxford, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': '1Oxford University, Oxford, United Kingdom.', 'institution_ids': ['https://openalex.org/I40120149']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.153, 'has_fulltext': False, 'cited_by_count': 1, 'citation_normalized_percentile': {'value': 0.462004, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 65, 'max': 72}, 'biblio': {'volume': '71', 'issue': '8_Supplement', 'first_page': '1737', 'last_page': '1737'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10755', 'display_name': 'HER2/EGFR in Cancer Research', 'score': 0.9967, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10755', 'display_name': 'HER2/EGFR in Cancer Research', 'score': 0.9967, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11016', 'display_name': 'Monoclonal and Polyclonal Antibodies Research', 'score': 0.9938, 'subfield': {'id': 'https://openalex.org/subfields/2741', 'display_name': 'Radiology, Nuclear Medicine and Imaging'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11395', 'display_name': 'Radiopharmaceutical Chemistry and Applications', 'score': 0.9662, 'subfield': {'id': 'https://openalex.org/subfields/2741', 'display_name': 'Radiology, Nuclear Medicine and Imaging'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/neratinib', 'display_name': 'Neratinib', 'score': 0.97586334}, {'id': 'https://openalex.org/keywords/skbr3', 'display_name': 'SKBR3', 'score': 0.6537655}], 'concepts': [{'id': 'https://openalex.org/C2779413316', 'wikidata': 'https://www.wikidata.org/wiki/Q6995920', 'display_name': 'Neratinib', 'level': 5, 'score': 0.97586334}, {'id': 'https://openalex.org/C2779786085', 'wikidata': 'https://www.wikidata.org/wiki/Q412616', 'display_name': 'Trastuzumab', 'level': 4, 'score': 0.96732134}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.6796396}, {'id': 'https://openalex.org/C191560914', 'wikidata': 'https://www.wikidata.org/wiki/Q7390592', 'display_name': 'SKBR3', 'level': 5, 'score': 0.6537655}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.4262395}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.3920313}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.39014792}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.3764718}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.31306198}, {'id': 'https://openalex.org/C96232424', 'wikidata': 'https://www.wikidata.org/wiki/Q4118072', 'display_name': 'Cancer cell', 'level': 3, 'score': 0.25138792}, {'id': 'https://openalex.org/C530470458', 'wikidata': 'https://www.wikidata.org/wiki/Q128581', 'display_name': 'Breast cancer', 'level': 3, 'score': 0.24894142}, {'id': 'https://openalex.org/C2994423619', 'wikidata': 'https://www.wikidata.org/wiki/Q9103', 'display_name': 'Human breast', 'level': 4, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2011-1737', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.85}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3025149516', 'https://openalex.org/W3006441332', 'https://openalex.org/W3000239990', 'https://openalex.org/W2808686791', 'https://openalex.org/W2270690696', 'https://openalex.org/W2071686517', 'https://openalex.org/W2032610835', 'https://openalex.org/W2012480315', 'https://openalex.org/W1601510090', 'https://openalex.org/W1525807619'], 'abstract_inverted_index': {'Abstract': [0], 'Overexpression': [1], 'of': [2, 8, 15, 25, 46, 66, 102, 111, 185, 191, 301, 372, 422, 427], 'HER2': [3, 27, 409], 'is': [4, 12], 'seen': [5], 'in': [6, 35, 38, 57, 88, 123, 145, 153, 167, 200, 228, 234, 307, 369, 384, 399, 403], '15-20%': [7], 'breast': [9, 411], 'cancer': [10, 412], 'and': [11, 54, 92, 96, 115, 117, 125, 140, 155, 166, 173, 187, 211, 219, 231, 255, 273, 277, 297, 319, 331, 364, 376, 378, 407], 'a': [13, 19, 43, 62, 196, 235, 381], 'predictor': [14], 'poor': [16], 'prognosis.': [17], 'Trastuzumab,': [18], 'monoclonal': [20], 'antibody': [21], 'to': [22, 32, 51, 70, 85, 97, 304, 315, 380, 396], 'the': [23, 26, 73, 100, 183, 189, 209, 293, 359, 370, 423, 428], 'ECD': [24], 'receptor,': [28], 'has': [29, 129, 142], 'been': [30, 131, 143], 'shown': [31], 'increase': [33, 152, 306], 'survival': [34], 'patients': [36, 47], 'especially': [37], 'combination': [39, 119, 168, 190, 220, 244, 400], 'with': [40, 157, 169, 180, 193, 245, 329, 362, 401], 'chemotherapy.': [41], 'However,': [42, 310], 'significant': [44], 'number': [45], 'do': [48], 'not': [49, 136], 'respond': [50], 'trastuzumab': [52, 60, 89, 105, 116, 134, 146, 159, 170, 181, 194, 246, 276, 294, 302, 317, 330, 346, 365, 388, 402, 405], 'treatment': [53, 164, 179, 223, 241, 261, 279, 312, 328, 347, 361, 389], 'resistance': [55, 87, 318, 353], 'develops': [56], 'those': [58], 'given': [59], 'as': [61], 'monotherapy.': [63], 'The': [64, 109], 'purpose': [65], 'this': [67, 141], 'study': [68], 'was': [69, 204, 262, 280, 313, 333, 366], 'investigate': [71], 'whether': [72], 'small': [74], 'molecule': [75], 'irreversible': [76], 'tyrosine': [77], 'kinase': [78], 'inhibitor': [79], 'neratinib': [80, 103, 118, 163, 192, 218, 240, 260, 278, 288, 311, 332, 341, 363, 395], '(HKI-272)': [81], 'could': [82], 'be': [83, 349, 397], 'used': [84, 398], 'overcome': [86], 'resistant': [90, 210, 232, 295, 408], 'BT474': [91, 126, 254, 298], 'SKBR3': [93, 124, 213, 256, 296], 'cell': [94, 107, 268, 285, 308, 322, 338, 385], 'lines': [95], 'look': [98], 'at': [99, 266, 283, 336], 'effects': [101, 110], 'on': [104, 207, 253], 'naive': [106, 406], 'lines.': [108], 'acute': [112, 158, 162, 178, 216], 'trastuzumab,': [113, 217], 'neratinib,': [114], 'treatments': [120], 'were': [121], 'investigated': [122], 'cells.': [127], 'It': [128], 'already': [130], 'established': [132], 'that': [133, 259, 274, 345, 358], 'does': [135], 'abolish': [137], 'pHER2': [138, 154, 174, 225], 'expression': [139, 184], 'implicated': [144], 'resistance.': [147], 'Western': [148], 'blotting': [149], 'showed': [150, 258, 357], 'an': [151, 305], 'pERK': [156, 172], 'treatment.': [160], 'Conversely,': [161], 'alone': [165, 289], 'reduced': [171, 247], 'expression.': [175, 201], 'Furthermore,': [176, 326], 'although': [177], 'decreased': [182], 'pHER3': [186], 'pAKT,': [188], 'gave': [195], 'much': [197, 263], 'greater': [198, 382], 'decrease': [199, 383], 'Fluorescence': [202], 'microscopy': [203], 'also': [205], 'performed': [206], 'both': [208, 229, 404], 'native': [212, 230], 'cells': [214, 233, 257], 'after': [215], 'treatments.': [221], 'Trastuzumab': [222], 'increased': [224], 'membrane': [226, 248], 'localisation': [227], 'dose': [236], 'dependent': [237], 'manner,': [238], 'whilst': [239], 'or': [242], 'its': [243], 'pHER2.': [249], 'Cell': [250], 'viability': [251, 269, 286, 323, 339, 386], 'experiments': [252], 'more': [264, 281, 334, 367], 'effective': [265, 282, 335, 368], 'reducing': [267, 284, 337], 'than': [270, 287, 340, 387], 'trastuzumab(p=0.0078,': [271], 'p=0.0499)': [272], 'combined': [275, 327, 360], '(p=0.0028,': [290], 'p=0.0148).': [291], 'In': [292], 'cells,': [299], 'withdrawal': [300], 'lead': [303], 'viability.': [309], 'able': [314], 'reverse': [316], 'significantly': [320], 'reduce': [321], '(p=0.0022,': [324], 'p=0.0087).': [325], 'alone(p=0.0087,': [342], 'p=0.0260)': [343], 'suggesting': [344], 'should': [348], 'continued': [350], 'even': [351], 'when': [352], 'develops.': [354], 'These': [355], 'results': [356], 'inhibition': [371], 'pHER2,': [373], 'pHER3,': [374], 'pAkt': [375], 'pERK,': [377], 'led': [379], 'alone.': [390], 'We': [391], 'would': [392], 'therefore': [393], 'recommend': [394], 'over-expressing': [410], 'patients.': [413], 'Citation': [414], 'Format:': [415], '{Authors}.': [416], '{Abstract': [417], 'title}': [418], '[abstract].': [419], 'In:': [420], 'Proceedings': [421], '102nd': [424], 'Annual': [425], 'Meeting': [426], 'American': [429], 'Association': [430], 'for': [431], 'Cancer': [432, 442], 'Research;': [433], '2011': [434], 'Apr': [435], '2-6;': [436], 'Orlando,': [437], 'FL.': [438], 'Philadelphia': [439], '(PA):': [440], 'AACR;': [441], 'Res': [443], '2011;71(8': [444], 'Suppl):Abstract': [445], 'nr': [446], '1737.': [447], 'doi:10.1158/1538-7445.AM2011-1737': [448]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2071686517', 'counts_by_year': [{'year': 2012, 'cited_by_count': 1}], 'updated_date': '2024-12-08T12:47:46.047189', 'created_date': '2016-06-24'}